Curvebeam AI (ASX:CVB) is building artificial intelligence tools to aid in bone separation and segmentation, empowering orthopedic surgeons to make 3D-based deformity measurements to inform clinical decisions. The current focus of management is to support its U.S. growth strategy and further its Stryker partnership | Investor presentation: https://wcsecure.weblink.com.au/pdf/CVB/02800840.pdf
QXR
0.005
66.7%
LSR
0.01
-44.4%
CZN
0.003
50%
SRH
0.11
-37.1%
MHC
0.024
41.2%
PAB
0.002
-33.3%
MSG
0.007
40%
DY6
0.1
-25.9%
CUF
0.008
33.3%
1AD
0.003
-25%
DTM
0.004
33.3%
GGE
0.003
-25%
RGT
0.15
30.4%
ENV
0.007
-22.2%
HCT
0.056
30.2%
NTU
0.026
-21.2%
LCY
0.01
25%
BYH
0.004
-20%
TYX
0.005
25%
ICG
0.004
-20%
WMG
0.21
23.5%
RDS
0.004
-20%
29M
0.16
23.1%
FGH
0.009
-18.2%
PUA
0.016
23.1%
RR1
0.009
-18.2%
VRX
0.07
22.8%
SRL
0.43
-18.1%
PHO
0.066
22.2%
VHM
0.27
-16.9%
BGD
0.67
20.7%
ANR
0.005
-16.7%
BMR
0.175
20.7%
ERL
0.005
-16.7%
ATH
0.012
20%
PLC
0.01
-16.7%
BKT
0.024
20%
PGH
0.83
-14.4%
EM2
0.006
20%
AN1
0.006
-14.3%
